Overcoming radioresistance in head and neck squamous cell carcinoma. (December 2016)

• Record Type: Journal Article
• Authors: Yamamoto, Vicky N.; Thylur, David S.; Bauschard, Michael; Schmale, Isaac; Sinha, Uttam K.
• Is Part Of: Oral oncology. Volume 63(2016:Dec.)
• Page Start: 44
• Page End: 51
• Publication Date: 2016-12
• Subjects: Radiotherapy -- Head and neck cancer -- Head and neck squamous cell carcinoma -- Radiation-sensitizing agents -- Molecular targeted therapy -- Radiation resistance -- Radioresistance -- DNA damage; Mouth -- Cancer -- Periodicals; Mouth -- Tumors -- Periodicals; Mouth Diseases -- Periodicals; Mouth Neoplasms -- Periodicals; Bouche -- Cancer -- Périodiques; Bouche -- Tumeurs -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9943105
• DOI: 10.1016/j.oraloncology.2016.11.002
• Languages: English
• ISSNs: 1368-8375

Abstract

Highlights: Detailed mechanisms and key players of radioresistance are discussed. In general, modulation of DNA damage response contributes to radioresistance. EGFR inhibition has been a main focus for radiosensitization. Therapies to radiosensitize with highest translational promise are covered. Further work on this topic may lead to development of novel targeted therapies. Abstract: Radiation therapy plays an essential role in the treatment of head and neck squamous cell carcinoma (HNSCC), yet therapeutic efficacy is hindered by treatment-associated toxicity and tumor recurrence. In comparison to other cancers, innovation has proved challenging, with the epidermal growth factor receptor (EGFR) antibody cetuximab being the only new radiosensitizing agent approved by the FDA in over half a century. This review examines the physiological mechanisms that contribute to radioresistance in HNSCC as well as preclinical and clinical data regarding novel radiosensitizing agents, with an emphasis on those with highest translational promise.